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Design: Twenty	 patients	with	 primary	 adrenal	 insufficiency	 and	matched	 controls	
and	19	patients	with	 secondary	 adrenal	 insufficiency	 participated	 in	 this	 ancillary	
analysis	of	two	different	studies.
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1  | INTRODUC TION
Patients	with	primary	adrenal	insufficiency	(PAI)	due	to	autoimmune	
adrenalitis	 are	 thought	 to	 have	 no	 adrenal	 cortical	 function	 after	
long‐standing	disease	as	a	consequence	of	progressive	destruction	


























but	often	still	measurable.	The	clinical	 significance	of	 this	 residual	
production	is	unknown.	It	can	be	speculated	to	reduce	the	require-
ments	of	hormone	 replacement,	 affect	quality	of	 life,	or	 influence	













usually	 the	strategy	 is	chosen	to	 temporarily	withdraw	hydrocorti-
sone	 substitution.	Alternatively,	 this	problem	can	be	circumvented	
by	using	stable	isotope	dilution/mass	spectrometry,	but	these	tech-





only	 cortisol	 and	 cortisone	 in	 one	 run	 but	 also	 several	 precursor	









In	 this	 study,	we	 compared	 patients	with	 primary	 adrenal	 insuffi-
ciency	and	their	controls	from	a	cross‐sectional,	single‐centre,	case‐
control	 study	 with	 patients	 with	 secondary	 adrenal	 insufficiency	
from	a	randomized	double‐blind	crossover	study.
2.2 | Ethical considerations
In	both	 studies,	 ethical	 approval	was	obtained	 from	 the	 local	 eth-
ics	committee.	The	study	was	approved	by	the	University	Medical	
Center	 Groningen,	 the	 Netherlands	 and	 Sahlgrenska	 University	
Hospital,	Gothenburg,	Sweden.	Informed	consent	was	obtained	from	
all	participants	before	any	elements	of	the	study	were	performed.	
The	 study	 was	 conducted	 according	 to	 the	 latest	 Declaration	 of	
Helsinki.
2.3 | Subjects
2.3.1 | Patients with primary adrenal 





cruitment	 have	been	published	previously.13	 In	 short,	 adult	 patients	
from	western	Sweden,	diagnosed	with	primary	adrenal	 insufficiency	
K E Y W O R D S
11‐deoxycortisol,	adrenal	insufficiency,	aldosterone,	corticosterone,	cortisol,	hydrocortisone,	
precursors
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at	the	age	of	18	years	or	older,	were	invited	to	participate.	Matched	
control	 subjects	 from	 the	Gothenburg	 region	were	 recruited	 from	a	




2.3.2 | Patients with secondary adrenal 
insufficiency
This	 randomized	double‐blind	crossover	 study	was	performed	 in	a	
university	 hospital	 in	 Groningen,	 The	 Netherlands,	 between	 May	
2012	and	June	2013.	The	study	has	been	registered	with	ClinicalTrials.
gov	 with	 number	 NCT01546922.	 The	 study	 design	 and	 rationale	
have	 been	 published	 in	 detail	 previously.14	 In	 short,	 patients	 with	














run‐in	 period.	 The	 hydrocortisone	 dose	 during	 the	 run‐in	 period	
averaged	25	mg	per	day	 (0.31	mg/kg	body	weight).	After	the	run‐







daily	doses	 ranged	 from	30	 to	40	mg	per	day),	 taken	at	 the	 same	
time	 points	 of	 the	 day.	 In	 case	 of	 intercurrent	 illness,	 doubling	 or	
tripling	of	the	dose	was	allowed	for	a	maximum	of	7	successive	days.	
Compliance	 with	 study	 medication	 was	 assessed	 as	 described.14 
After	each	treatment	period,	blood	sample	drawing	1	hour	after	in-
gestion	of	 the	morning	dose	of	 hydrocortisone	was	done	 and	24‐
hour	 urine	 collection	was	 performed.	 The	 initial	 study	 population	
existed	47	patients	that	completed	both	study	periods.14	For	present	
analysis,	samples	of	19	patients	were	available.
2.3.3 | Exposure to and pharmacokinetics of 
hydrocortisone
In	 patients	 with	 secondary	 adrenal	 insufficiency,	 estimations	
of	 the	 individual	 pharmacokinetic	 parameters	 were	 calculated	
as	 described	 in	 detail	 elsewhere.15	 In	 short,	 the	 Kinpop	 module	
of	MwPharm	 version	 3.81	was	 used	 to	 calculate	 a	 one‐compart-
ment	 and	 two‐compartment	 population	 model	 for	 plasma	 total	
cortisol.	The	models	were	calculated	using	an	 iterative	 two‐stage	
Bayesian	 procedure	 and	 validated	with	 the	Monte	 Carlo	 analysis	
using	MwPharm.	The	one‐compartment	model	showed	the	best	fit,	
as	measured	with	the	relative	root	mean	squared	error	which	 is	a	
measure	of	precision,	and	was	kept	as	 the	final	model	 for	 further	
pharmacokinetic	 analysis.	 Individual	 pharmacokinetic	 parameter	
was	calculated	by	maximum	a	posteriori	Bayesian	estimation	using	
the	noncompartment	 final	model	 for	plasma	 total	 cortisol	 for	 the	





hydrocortisone	 substitution	 or	 as	 a	 consequence	 of	 both	 residual	
endogenous	cortisol	production	and	substitution	therapy.	We	there-







lution	 liquid	 chromatography	 tandem	mass	 spectrometry	 (LC‐MS/
MS).	The	measurement	of	these	steroids	 in	plasma	was	performed	
essentially	 as	 described	 by	 Hawley	 et	 al,	 using	 cortisol‐D4,	 E‐D7,	
11S‐13C3,	21S‐D4,	B‐D4,	and	11DOC‐13C3	as	internal	standard.16 
In	short,	200	µL	of	plasma	was	used,	and	 isotope	 labelled	 internal	
standards	were	added	and	incubated	for	10	minutes.	Samples	were	
extracted	using	a	400	µL	supported	liquid	extraction	plate	(Biotage).	











in	 positive	 electrospray	 ionization	 and	 selective	 reaction	monitor-
ing	mode.	MS	settings	and	transitions	are	shown	in	the	supplement	
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2.3.5 | Statistics
Data	 are	 presented	 as	mean	±	 standard	 deviation	 or	median	 (in-
terquartile	 range)	 when	 appropriate.	 Normality	 of	 the	 data	 was	
checked	using	QQ‐plots	and	histograms.	Parametric	statistics	were	































3.3 | Exposure to and pharmacokinetics of 
hydrocortisone in SAI patients
Patients	with	SAI	who	had	11‐deoxycortisol	concentrations	below	
the	 median	 on	 either	 the	 lower	 dose	 or	 the	 higher	 dose	 of	 HC	




TA B L E  1  Clinical	characteristics	of	study	patients
 Controls (n = 20)
Primary adrenal insuffi‐
ciency patients (n = 20)
Secondary adrenal insufficiency patients 
(n = 19) P‐Value a
Age	(y) 54	±	17 54	±	17 52	±	12 0.747
Sex	(males/females),	n 4/16 4/16 9/10  
Age	at	diagnosis	(y) na 40	±	18 32	±	19 0.169
Body	weight	(kg) 69.3	±	13.5 69.7	±	13.3 81.6	±	14.7 0.012
BMI	(kg/m2) 23.5	±	3.4 24.7	±	4.7 27.2	±	5.1 0.132









    
Total	daily	dose	(mg/d) - 27.8	±	7.0 Lower	dose:	17.8	±	2.3  
  Higher	dose:	35.5	±	4.7  
Morning	dose	(mg) - 16.0	±	4.8 Lower	dose:	9.1	±	1.2  
  Higher	dose:	18.2	±	2.5  
Weight‐corrected	daily	morning	
dose	(mg/kg	BW)
 0.23	±	0.06 Lower	dose:	0.11	±	0.01  
  Higher	dose:	0.23	±	0.03  
Number	of	daily	dosings,	n	=	1/2/3 - 1/16/3 0/0/19  
Fludrocortisone	dose	(µg/d) - 75	±	26 -  









tifiable.	 Remarkable	 is	 that	 all	 patients	 had	 long‐standing	 disease	






long‐standing	 absence	of	 significant	 amounts	of	ACTH	and	 in	 the	
presence	 of	 negative	 feedback	 provided	 by	 exogenous	 hydrocor-




















therapy,	as	 is	 the	case	 in	our	patient	group	who	were	on	approxi-
mately	10‐20	years	after	their	diagnosis	of	adrenal	insufficiency.
Techniques	involving	stable	isotopes	may	give	insight	in	patients	




profiling	 by	means	 of	 LC‐MS/MS	 is	 a	 newly	 developed	 technique	
available	since	a	few	years	and	has	been	used	for	the	evaluation	of	
secreting	adrenal	adenomas.20-22	Mass	spectrometry	is	an	efficient	
 11‐deoxycortisol 11‐deoxycorticosterone corticosterone
Controls	(%) 100 95 95
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5 0 0
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and	specific	utility	superior	 in	this	context	to	the	cumbersome	im-
muno‐assays	 and	 without	 disturbing	 cross‐reactivity.21,23	 We	 de-
veloped	 a	 LC‐MS/MS	 that	 combines	 a	 low	 LOQ	 for	 all	 measured	
steroids	(in	the	low	picomolar	range)	and	short	retention	time	(Table	
S1),	making	it	possible	to	measure	multiple	samples	in	a	short	period	
of	 time.	Another	strength	of	 the	present	study	 is	 the	pharmacoki-





ciency	may	have	 interesting	 implications.	For	example,	 low	concen-
trations	of	11‐deoxycortisol	or	corticosterone	may	affect	quality	of	
life	or	cognition.	In	agreement	with	this,	Nixon	and	co‐workers	have	








hydrocortisone	 tapering	 regimes	 to	 assess	 recovery	 of	 adrenal	
function	or	in	patients	after	pituitary	surgery	who	fail	to	show	an	
adequate	 basal	 or	 stimulated	 cortisol	 and	 are	 often	 put	 on	 life-
long	hydrocortisone	replacement	therapy	without	additional	test-
ing.	 Secondly,	 11‐deoxycortisol	 may	 be	 an	 indicator	 (biomarker)	
of	oversubstitution	with	hydrocortisone	 in	SAI.	Current	practice	
is	 to	make	 this	 assessment	 on	 clinical	 grounds,	 but	well‐defined	
criteria	 are	 lacking.	 In	 fact,	 due	 to	 the	 complexity	 of	 the	 entire	
HPA	axis	physiology	with	its	 interindividual	differences	in	gluco-
corticoid	sensitivity	personalized	treatment	doses	are	necessary.	















11 deoxycortisol Below  
median (N = 10)
11 deoxycortisol Above 






















































PAI	patients	with	 the	 initial	 assumption	 that	 these	were	 complete	
negative	 controls,	 thus	 establishing	 that	 no	 extra‐adrenal	 produc-
tion	of	cortisol	precursors	was	present.	Indeed,	this	was	the	case	in	
many	patients	with	PAI,	 confirming	 that	 the	 enzymatic	machinery	
to	produce	cortisol	is	only	present	in	the	adrenal	glands.	However,	
much	to	our	surprise,	half	of	the	patients	with	autoimmune	primary	
adrenal	 insufficiency	 showed	 some	 evidence	 of	 adrenal	 cortical	
functioning.	Additional	testing	is	necessary	to	confirm	this	and	gain	
further	 insight.	Thirdly,	the	 inclusion	of	dynamic	testing	of	adrenal	









We	 conclude	 that	 cortisol	 synthesis	 is	 ongoing	 in	 SAI	 patients	
based	on	concentrations	of	11‐deoxycortisol,	albeit	at	very	low	lev-
els	because	no	increase	total	cortisol	exposure	was	observed	in	SAI	
patients	 with	 higher	 11‐deoxycortisol	 concentrations.	 This	 seems	
plausible,	 but	 additional	 data	 validated	 against	 other	 methods	 in	
healthy	volunteers	and	patients	are	needed	to	gain	 further	 insight	
in	 this.	 However,	 when	 looking	 at	 the	 absolute	 concentrations	 of	
11‐deoxycortisol,	 which	 appears	 to	 be	 <1/1000th	 of	 the	 normal	
cortisol	 concentrations	 at	 9	 am,	 one	 comes	 to	 similar	 conclusions.	
In	conclusion,	adrenal	corticosteroid	production	is	likely	to	continue	
during	treatment	in	a	considerable	percentage	of	patients	with	PAI	
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